Cytokines, autoantibodies and astrocytes in the pathology of Aicardi-Goutieres syndrome (AGS)

Cytokines, autoantibodies and astrocytes in the pathology of Aicardi-Goutieres syndrome (AGS) - NIMBL = Nuclease Immune Mediated Brain and Lupus-like conditions

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34842

Enrollment

Registered

2010-08-11

Start date

2010-03-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital brain inflammation congenital encephalopathy

Interventions

None listed

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: AGS as diagnosed by pediatric neurologist

Exclusion criteria

Exclusion criteria: no similarity to AGS

Design outcomes

Primary

Measure	Time frame
We have previously shown that this test helps to discriminate AGS from viral disease. This current study will expand these data by screening blood and CSF from AGS patients and controls for a more extensive set of cytokines, chemokines and growth factors using available Luminex technology. Primary outcome measures: - new sensitive diagnostics for AGS in blood and/or CSF - determine the sensitivity of these parameters over time (since the inflammatory features in AGS ultimately wane ["burning out"]) - serum autoantibodies against standard autoantigens and tissue materials (routine diagnostics, including brain) - assess the time course of cytokines and presence or appearance of autoantibodies in relation to clinical disease	—

Measure

Time frame

We have previously shown that this test helps to discriminate AGS from viral disease. This current study will expand these data by screening blood and CSF from AGS patients and controls for a more extensive set of cytokines, chemokines and growth factors using available Luminex technology. Primary outcome measures: - new sensitive diagnostics for AGS in blood and/or CSF - determine the sensitivity of these parameters over time (since the inflammatory features in AGS ultimately wane ["burning out"]) - serum autoantibodies against standard autoantigens and tissue materials (routine diagnostics, including brain) - assess the time course of cytokines and presence or appearance of autoantibodies in relation to clinical disease

—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results